Oxomemazine

Oxomemazine is a phenothiazine-based histamine H1-receptor blocker. Oxomemazine is a selective antagonist for muscarinic M1 receptor, displays about 20-fold difference in the affinity for high (Ki = 84 nM, M1 receptor) and low (Ki = 1.65 μM, M2 receptor) affinity sites. Oxomemazine is an antihistamine and anticholinergic agent used for the study of cough treatment. Oxomemazine is protective against anaphylactic microshock in guinea pigs[1][2][3].

Product Specifications

CAS Number

[3689-50-7]

UNSPSC

12352005

Hazard Statement

H301, H311, H330

Target

Histamine Receptor; mGluR

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/oxomemazine.html

Purity

99.18

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(CN1C2=C(C=CC=C2)S(C3=CC=CC=C13)(=O)=O)CN(C)C

Molecular Formula

C18H22N2O2S

Molecular Weight

330.44

Precautions

H301, H311, H330

References & Citations

[1]S W Lee, et al.Selectivity of oxomemazine for the M1 muscarinic receptors.Arch Pharm Res. 1994 Dec;17 (6) :443-51.|[2]M S Siddegowda, et al.Oxomemazine hydro-chloride. Acta Crystallogr Sect E Struct Rep Online. 2011 Aug 1;67 (Pt 8) :o1875.|[3]HERXHEIMER H, et al. THE EFFECT OF SOME NEW ANTIHISTAMINES ON THE ANAPHYLACTIC MICROSHOCK OF THE GUINEA-PIG. Br J Pharmacol Chemother. 1963 Dec;21 (3) :414-8.